3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Plasma cell
1
Gynecologic
1
Breast
1
Conditions
Multiple Myeloma
1112
Recurrence
195
Neoplasms
89
Lymphoma
89
Neoplasms, Plasma Cell
88
Lymphoma, Non-Hodgkin
86
Leukemia, Myeloid, Acute
53
Hematologic Neoplasms
51
Leukemia, Lymphocytic, Chronic, B-Cell
44
Leukemia
37
Myelodysplastic Syndromes
33
Lymphoma, Large B-Cell, Diffuse
31
Hodgkin Disease
31
Immunoglobulin Light-chain Amyloidosis
30
Breast Neoplasms
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Hematologic Diseases
25
Prostatic Neoplasms
19
Paraproteinemias
19
Lymphoma, B-Cell
19
Amyloidosis
19
Lymphoma, Mantle-Cell
18
Ovarian Neoplasms
17
Carcinoma, Non-Small-Cell Lung
17
Waldenstrom Macroglobulinemia
16
Lung Neoplasms
16
Lymphoma, Follicular
15
Lymphoproliferative Disorders
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Blood Protein Disorders
14
Interventions
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
AIDS-related Kaposi sarcoma
×
Plasma cell
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled